Yes. Currently, researchers have developed a nanoparticle-based concentrate for injection (Nab-paclitaxel), which is a water-soluble formulation of paclitaxel. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby inhibiting cell division. Compared with paclitaxel alone, the nanodispersion-based formulation uses less toxic solvents and a larger dose, resulting in higher paclitaxel concentrations at the tumor site and better safety.

In addition, they compared the antitumor efficacy and toxicity of Nab-paclitaxel with paclitaxel in vitro and in a mouse endometrial cancer model. Nab-paclitaxel is more effective than paclitaxel in inhibiting cancer cell growth. Nab-paclitaxel also causes apoptosis and cell cycle G1 arrest more effectively than paclitaxel. Similar effects were observed in a mouse model of endometrial cancer. However, it remains to be verified in clinical applications.

References:

[1] Paclitaxel Injection Concentrate for Nanodispersion[J]. Definitions, 2020. DOI:10.32388/3574l6.

[2] JING HUANG. Nanoparticle Albumin-Bound Paclitaxel is More Effective Than Paclitaxel in Experimental Endometrial Cancer[J]. Science of Advanced Materials, 2022. DOI:10.1166/sam.2022.4251.